U.S. markets close in 2 hours 7 minutes

Bellicum Pharmaceuticals, Inc. (BLCM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2200-0.0400 (-1.77%)
As of 1:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.2600
Bid2.2700 x 2200
Ask2.2800 x 1200
Day's Range2.2200 - 2.4093
52 Week Range2.2200 - 8.1500
Avg. Volume299,264
Market Cap18.643M
Beta (5Y Monthly)1.71
PE Ratio (TTM)4.15
EPS (TTM)0.5350
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BLCM

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bellicum Pharmaceuticals, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
  • GlobeNewswire

    Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

    HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference (Virtual). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 13, 2021 and will remain accessible for 90 days in the Events and Presenta

  • Benzinga

    38 Stocks Moving In Wednesday's Mid-Day Session

    Gainers Focus Universal Inc. (NASDAQ: FCUV) shares jumped 108.2% to $10.62. The stock started trading on Nasdaq Capital Market yesterday. Sequential Brands Group, Inc. (NASDAQ: SQBG) gained 36.4% to $7.00. Sequential Brands Group recently commenced voluntary Chapter 11 proceedings. Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) surged 30% to $3.89 after the company, and MD Anderson, announced an additional license agreement for use of CaspaCIDe safety switch. ABVC BioPharma, Inc. (NASDAQ: ABVC) s

  • GlobeNewswire

    Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

    HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the sa